Boffito M - Search Results

1

Lopinavir protein binding in vivo through the 12-hour dosing interval.

Boffito M, Hoggard PG, Lindup WE, Bonora S, Sinicco A, Khoo SH, Di Perri G, Back DJ. Boffito M, et al. Ther Drug Monit. 2004 Feb;26(1):35-9. doi: 10.1097/00007691-200402000-00008. Ther Drug Monit. 2004. PMID: 14749547 Clinical Trial.

2

The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

Boffito M, Hoggard PG, Reynolds HE, Bonora S, Meaden ER, Sinicco A, Di Perri G, Back DJ. Boffito M, et al. Br J Clin Pharmacol. 2002 Sep;54(3):262-8. doi: 10.1046/j.1365-2125.2002.01663.x. Br J Clin Pharmacol. 2002. PMID: 12236846 Free PMC article.

3

Simultaneous determination of rifampicin and efavirenz in plasma.

Boffito M, Tija J, Reynolds HE, Hoggard PG, Bonora S, Di Perri G, Back DJ. Boffito M, et al. Ther Drug Monit. 2002 Oct;24(5):670-4. doi: 10.1097/00007691-200210000-00015. Ther Drug Monit. 2002. PMID: 12352941

4

Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.

Dickinson L, Back D, Pozniak A, Khoo S, Boffito M. Dickinson L, et al. Among authors: boffito m. Ther Drug Monit. 2007 Jun;29(3):361-7. doi: 10.1097/FTD.0b013e3180683b25. Ther Drug Monit. 2007. PMID: 17529895

5

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.

Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A, Gazzard B, Moyle G. Boffito M, et al. Antivir Ther. 2008;13(7):901-7. Antivir Ther. 2008. PMID: 19043924 Clinical Trial.

6

Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment.

Boffito M, Rossati A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):341-2. doi: 10.1089/088922202753519115. AIDS Res Hum Retroviruses. 2002. PMID: 11897035 No abstract available.

7

Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting.

Boffito M, Bonora S, Raiteri R, Reynolds HE, Hoggard PG, Sinicco A, Back DJ, Di Perri G. Boffito M, et al. Ther Drug Monit. 2002 Aug;24(4):574-6. doi: 10.1097/00007691-200208000-00021. Ther Drug Monit. 2002. PMID: 12142647 Clinical Trial. No abstract available.

8

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.

Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Di Garbo A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. AIDS. 2002 Oct 18;16(15):2081-3. doi: 10.1097/00002030-200210180-00015. AIDS. 2002. PMID: 12370509

9

Lopinavir/ritonavir absorption in a gastrectomized patient.

Boffito M, Lucchini A, Maiello A, Dal Conte I, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. AIDS. 2003 Jan 3;17(1):136-7. doi: 10.1097/00002030-200301030-00023. AIDS. 2003. PMID: 12478084 No abstract available.

10

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.

Boffito M, Back DJ, Hoggard PG, Caci A, Bonora S, Raiteri R, Sinicco A, Reynolds HE, Khoo S, Di Perri G. Boffito M, et al. AIDS. 2003 May 2;17(7):1107-8. doi: 10.1097/00002030-200305020-00029. AIDS. 2003. PMID: 12700470 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

363 results

Search Page

Filters